Egg protein formulations and methods of manufacture thereof
The present technology relates generally to formulations comprising egg white protein, methods of manufacturing egg protein formulations and uses for egg protein formulations. In particular, several embodiments are directed to egg protein formulations for oral administration in immunotherapy of subjects affected by egg allergies.
1. A method of manufacturing a packaged pharmaceutical formulation for the treatment of egg allergy in a subject, comprising: a) determining the concentrations of ovomucoid, ovalbumin, and lysozyme proteins in a composition of egg white protein by one or more analytical methods; b) comparing the concentrations of the proteins to the concentrations of a reference standard; c) selecting a composition for treatment of egg allergy in a subject; and d) packaging the selected composition in a container, wherein the selected composition contains at least the concentrations of ovomucoid, ovalbumin, and lysozyme protein as the reference standard.
2. The method of claim 1 , wherein the analytic method is size exclusion chromatography.
3. The method of claim 2 , wherein the size exclusion chromatography is performed using high-performance liquid chromatography (HPLC).
4. The method of claim 1 , wherein the one or more analytical methods comprises an enzyme-linked immunosorbent assay (ELISA).
5. The method of claim 1 , wherein the one or more analytical methods comprises a high-performance liquid chromatography (HPLC) assay.
6. The method of claim 5 , wherein the one or more analytical methods further comprises an enzyme-linked immunosorbent assay (ELISA).
7. The method of claim 1 , comprising determining a concentration of total protein in the composition of egg white protein.
8. The method of claim 1 , wherein the concentrations of ovomucoid, ovalbumin, and lysozyme proteins in the composition of egg white protein are determined after a storage period.
9. The method of claim 8 , wherein the storage period is 3 or more months.
10. The method of claim 1 , wherein the concentration of ovomucoid in the selected composition is about 0.16 mg to about 0.24 mg ovomucoid for 1.0 mg of total egg protein.
11. The method of claim 1 , wherein the concentration of ovalbumin in the selected composition is about 0.46 mg to about 0.54 mg ovalbumin for 1.0 mg of total egg protein.
12. The method of claim 1 , wherein the concentration of lysozyme in the selected composition is about 0.01 mg to about 0.09 mg lysozyme for 1.0 mg of total egg protein.
13. The method of claim 1 , wherein the container is a capsule.
14. The method of claim 1 , wherein the container is a sachet.
15. The method of claim 1 , wherein the packaging the selected composition comprises dosing the selected composition at a target unit weight of egg white protein.
16. The method of claim 15 , wherein the target unit weight of egg white protein is between about 0.2 mg and about 1000 mg egg white protein.
17. The method of claim 16 , wherein the target unit weight of egg white protein is about 0.2 mg egg white protein.
18. The method of claim 16 , wherein the target unit weight of egg white protein is about 1.0 mg egg white protein.
19. The method of claim 16 , wherein the target unit weight of egg white protein is about 10 mg egg white protein.
20. The method of claim 16 , wherein the target unit weight of egg white protein is about 100 mg egg white protein.
21. The method of claim 16 , wherein the target unit weight of egg white protein is about 300 mg egg white protein.